Therapeutics(LENZ)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

LENZ Therapeutics

休市中 04-24 16:00:00 EDT

9.38

+0.23

+2.51%

盘后9.38

+0.000.00%

19:38 EDT

最高9.48	最低8.95	成交量65.61万
今开9.17	昨收9.15	日振幅5.79%
总市值2.93亿	流通市值1.47亿	总股本3,129万
成交额609.13万	换手率4.18%	流通股本1,569万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"LENZ","market":"US","secType":"STK","nameCN":"Therapeutics","latestPrice":9.38,"timestamp":1777060800000,"preClose":9.15,"halted":0,"volume":656146,"hourTrading":{"tag":"盘后","latestPrice":9.38,"preClose":9.38,"latestTime":"19:38 EDT","volume":13696,"amount":128486.4,"timestamp":1777073913017,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.02513661202185797,"floatShares":15692500,"shares":31289969,"eps":-2.85,"marketStatus":"休市中","change":0.23,"latestTime":"04-24 16:00:00 EDT","open":9.17,"high":9.48,"low":8.95,"amount":6091348.450796,"amplitude":0.057923,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.85,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1777276800000},"marketStatusCode":7,"adr":0,"listingDate":1624593600000,"exchange":"NASDAQ","adjPreClose":9.15,"preHourTrading":{"tag":"盘前","latestPrice":9.18,"preClose":9.15,"latestTime":"09:28 EDT","volume":1039,"amount":9664.578512,"timestamp":1777037284065,"change":0.03,"changeRate":0.003279,"amplitude":0.034973},"postHourTrading":{"tag":"盘后","latestPrice":9.38,"preClose":9.38,"latestTime":"19:38 EDT","volume":13696,"amount":128486.4,"timestamp":1777073913017,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.939016,"impliedVol":1.3398,"impliedVolPercentile":0.9801},"requestUrl":"/m/hq/s/LENZ","defaultTab":"news","newsList":[{"id":"2629852486","title":"美国FDA拒绝批准Grace Therapeutics脑卒中药物","url":"https://stock-news.laohu8.com/highlight/detail?id=2629852486","media":"环球市场播报","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629852486?lang=zh_cn&edition=full","pubTime":"2026-04-24 02:43","pubTimestamp":1776969780,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局近日已向Grace Therapeutics发出完整回应函，拒绝批准其候选药物治疗特定类型脑卒中（中风）的上市申请。FDA在函件中指出，根据现有数据，暂无法确认该药物的临床获益大于风险，并要求公司在药品获批前补充相关的临床试验数据或生产质量控制信息。　　Grace Therapeutics方面随即回应称，正对FDA的反馈进行详细评估。　　此次拒绝为该公司的新药上市之路增加了新的不确定性，至于Grace是选择提起上诉还是重新提交申请，还有待公司进一步披露。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-04-24/doc-inhvpqks5066320.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4007","BK4539","BK4588","LENZ","BK4139","LABU","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115266921","title":"Trevi Therapeutics完成1.73亿美元承销发行 承销商全额行使超额配售权","url":"https://stock-news.laohu8.com/highlight/detail?id=1115266921","media":"投资观察","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1115266921?lang=zh_cn&edition=full","pubTime":"2026-04-21 04:08","pubTimestamp":1776715692,"startTime":"0","endTime":"0","summary":"临床阶段生物制药公司Trevi Therapeutics近日宣布，其此前公布的承销公开发行已正式完成。本次发行以每股13.00美元的价格公开发行13,340,000股普通股，其中包括承销商全额行使期权，以发行价额外购买的1,740,000股普通股。在扣除承销折扣和佣金前，本次发行总收益约为1.73亿美元。所有发行股份均由Trevi公司售出。Trevi拟将Haduvio作为口服纳布啡缓释片的商品名。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4604","LU0795875086.SGD","LU0971096721.USD","LU0106261372.USD","LU2111349929.HKD","BK4516","BK4007","LU1162221912.USD","LU2089283258.USD","LU0006306889.USD","LU2271345857.HKD","BK4139","LU0882574139.USD","LU2023251221.USD","LU2028103732.USD","LU1668664300.SGD","BK4555","LU0098860793.USD","LU1732799900.SGD","BK4534","LU1791710582.SGD","LU0106831901.USD","LU1363072403.SGD","LENZ","LU0314104364.USD","LU1732800096.USD","MS","LU1791710400.SGD","LU1720051017.SGD","BK4099","BK4539","LU0158827948.USD","LU1244550577.SGD","LU2133065610.SGD","LU0225283273.USD","LU0320765646.SGD","LU2089284900.SGD","LU1548497426.USD","LU0557290698.USD","RCC","LU1989772840.SGD","LU0234570918.USD","BK4581","LU0795875169.SGD","LU1989772923.USD","LU0912757837.SGD","LU1244550221.USD","BK4588","LU1074936037.SGD","03160","BK4504","BK4585","LU1244550494.USD","LU2347655156.SGD","LU0158827781.USD","IE00BZ1G4Q59.USD","LU0267386448.USD","LU0528227936.USD","TM","BK4127","IE00BKVL7J92.USD","LU2357305700.SGD","LU1720051108.HKD","TRVI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126480925","title":"Lenz Therapeutics向英国药监局提交Vizz®老花眼治疗药物上市许可申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1126480925","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1126480925?lang=zh_cn&edition=full","pubTime":"2026-04-20 20:00","pubTimestamp":1776686431,"startTime":"0","endTime":"0","summary":"Lenz Therapeutics公司已正式向英国药品和保健品监管局提交了Vizz®药物的上市许可申请，该药物主要用于治疗老花眼。此次申请标志着该疗法在英国市场商业化进程的重要一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4539","BK4139","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628578522","title":"美股异动 | 减肥药新贵Kailera Therapeutics(KLRA.US)登陆美股市场 开盘暴涨超50%","url":"https://stock-news.laohu8.com/highlight/detail?id=2628578522","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628578522?lang=zh_cn&edition=full","pubTime":"2026-04-18 00:00","pubTimestamp":1776441606,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，周五，减肥药新贵Kailera Therapeutics(KLRA.US)登陆美股市场，开盘暴涨超50%，报24.1美元，IPO价格为16美元。该公司创下2021年以来美国生物科技领域规模最大的IPO纪录。Kailera成立于2024年，是一家处于临床后期的生物科技公司，正在开发四种基于GLP-1的减肥药物，其中包括一款每周注射一次的药物和一款每日口服一次的药片，目前均已进入后期临床试验阶段。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1430273.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["KLRA","BK4539","BK4139","BK4007","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138495751","title":"Trevi Therapeutics宣布拟进行普通股公开发行","url":"https://stock-news.laohu8.com/highlight/detail?id=1138495751","media":"投资观察","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1138495751?lang=zh_cn&edition=full","pubTime":"2026-04-17 04:11","pubTimestamp":1776370286,"startTime":"0","endTime":"0","summary":"临床阶段生物制药公司Trevi Therapeutics今日宣布，已启动承销式公开发行，计划发售总值1.5亿美元的普通股。本次发行全部股份均由Trevi提供。公司还拟授予承销商30天超额配售选择权，可额外认购最多2250万美元的普通股，发行价格将扣除承销折扣与佣金。摩根士丹利、Leerink Partners、Cantor及Stifel担任此次发行的联席账簿管理人，Oppenheimer & Co.则出任牵头经理。Trevi计划将Haduvio作为口服纳布啡缓释片的商品名，其安全性与有效性尚未获得任何监管机构评估。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1244550577.SGD","LU0882574139.USD","LU1244550494.USD","BK4007","LU0971096721.USD","BK4504","LU1720051108.HKD","RCC","LU0158827781.USD","LU1720051017.SGD","LU1548497426.USD","LU1989772840.SGD","LU1244550221.USD","LU2028103732.USD","BK4139","BK4516","LENZ","LU2023251221.USD","LU2089283258.USD","LU0557290698.USD","LU0795875086.SGD","BK4604","BK4534","LU2111349929.HKD","LU2271345857.HKD","BK4127","BK4588","LU0225283273.USD","LU1732800096.USD","LU2133065610.SGD","TRVI","LU1989772923.USD","LU0320765646.SGD","LU0006306889.USD","LU0528227936.USD","LU0795875169.SGD","LU1363072403.SGD","LU1668664300.SGD","LU2357305700.SGD","LU1791710400.SGD","BK4539","LU1162221912.USD","IE00BKVL7J92.USD","BK4099","LU0158827948.USD","LU2347655156.SGD","LU0106261372.USD","LU0912757837.SGD","MS","IE00BZ1G4Q59.USD","LU0106831901.USD","LU0267386448.USD","LU0098860793.USD","LU1074936037.SGD","LU0314104364.USD","TM","03160","BK4555","LU1732799900.SGD","LU2089284900.SGD","LU1791710582.SGD","BK4585","BK4581","LU0234570918.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195745157","title":"Xilio Therapeutics任命Cheryl R. Blanchard博士加入董事会","url":"https://stock-news.laohu8.com/highlight/detail?id=1195745157","media":"投资观察","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1195745157?lang=zh_cn&edition=full","pubTime":"2026-04-16 19:33","pubTimestamp":1776339227,"startTime":"0","endTime":"0","summary":"马萨诸塞州沃尔瑟姆，2026年4月16日——临床阶段生物技术公司Xilio Therapeutics, Inc.今日宣布，任命Cheryl R. Blanchard博士加入公司董事会。公司同时公告，Christina Rossi已于2026年4月15日卸任董事职务。Cheryl R. Blanchard博士为Xilio带来逾30年领导经验，在生命科学企业具备深厚的科研、运营与商业管理背景。Xilio Therapeutics是一家临床阶段生物技术公司，致力于研发掩蔽型免疫肿瘤疗法，旨在显著提升癌症患者疗效的同时避免现有治疗引发的全身性副作用。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","BK4007","LENZ","XLO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115849765","title":"Structure Therapeutics任命Matthew Lang为首席运营官兼总法律顾问","url":"https://stock-news.laohu8.com/highlight/detail?id=1115849765","media":"投资观察","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1115849765?lang=zh_cn&edition=full","pubTime":"2026-04-15 04:07","pubTimestamp":1776197275,"startTime":"0","endTime":"0","summary":"旧金山，2026年4月14日——临床阶段全球生物制药公司Structure Therapeutics Inc.今日宣布，任命Matthew Lang, J.D. 为公司首席运营官兼总法律顾问。Lang先生在加入Structure Therapeutics时，已在全球生物制药机构拥有超过十五年的高管领导经验，其深厚专长涵盖法律、企业战略、合规、风险管理和业务发展等多个领域。Structure Therapeutics首席执行官Raymond Stevens博士表示：\"Matt是一位经验丰富的领导者，在引导组织实现增长和转型方面拥有卓越的业绩记录。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GPCR","BK4007","R","BK4599","BK4022","BK4232","LENZ","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627482480","title":"凝血障碍生物技术公司Hemab Therapeutics(COAG.US)申请在美上市 拟筹资至多1亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2627482480","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627482480?lang=zh_cn&edition=full","pubTime":"2026-04-13 14:36","pubTimestamp":1776062174,"startTime":"0","endTime":"0","summary":"Hemab Therapeutics上周五向SEC提交申请，计划通过首次公开募股(IPO)筹集至多1亿美元资金。","market":"sg","thumbnail":"https://img.zhitongcaijing.com/image/20260413/20260413143653_79739.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260413/20260413143653_79739.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1427652.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK4539","LENZ","BK4139","IPOS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626213871","title":"C4 Therapeutics与罗氏扩大合作，达成逾10亿美元新癌症药物协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2626213871","media":"环球市场播报","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626213871?lang=zh_cn&edition=full","pubTime":"2026-04-09 22:01","pubTimestamp":1775743260,"startTime":"0","endTime":"0","summary":"C4 Therapeutics周四宣布，已与瑞士制药巨头罗氏签署一项新的合作协议，共同研发新型癌症药物，交易总价值有望超过10亿美元。　　此次合作将聚焦于一种新兴的癌症疗法——降解剂-抗体偶联物。　　C4 Therapeutics：利用其专有的TORPEDO平台设计具有payload特性的降解剂候选分子。　　C4 Therapeutics将获得2000万美元的预付款。罗氏业务发展全球负责人Boris Zatra表示：“我们与C4 Therapeutics的关系建立在十年的信任和共同的科学追求之上”。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-04-09/doc-inhtxkar8629046.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4139","BK4007","CCCC","BK4539","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139966539","title":"Outlook Therapeutics完成500万美元公开发行募资","url":"https://stock-news.laohu8.com/highlight/detail?id=1139966539","media":"投资观察","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1139966539?lang=zh_cn&edition=full","pubTime":"2026-03-26 04:07","pubTimestamp":1774469224,"startTime":"0","endTime":"0","summary":"新泽西州艾斯林2026年3月25日电——专注于提升视网膜疾病治疗标准生物制药企业Outlook Therapeutics, Inc.今日宣布，已完成此前公布的2000万股普通股及配套认股权证公开发行。每份认股权证可额外认购1股普通股，发行单元定价为0.25美元。认股权证行权价每股0.25美元，即日生效，有效期五年。本次发行扣除承销费用前的总收益为500万美元。若认股权证全部以现金行权，公司有望再获约500万美元资金注入。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03160","BK4099","BK4588","LENZ","BK4139","BK4604","BK4539","BK4555","BK4585","TM","BK4007","OTLK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111228340","title":"Lenz Therapeutics公布2025年第四季度及全年财务业绩与近期企业动态","url":"https://stock-news.laohu8.com/highlight/detail?id=1111228340","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1111228340?lang=zh_cn&edition=full","pubTime":"2026-03-24 20:02","pubTimestamp":1774353743,"startTime":"0","endTime":"0","summary":"Lenz Therapeutics近日披露了2025年第四季度及全年的财务数据，并同步更新了公司近期的战略进展与重要里程碑。此次公布的信息全面展现了企业在财务运营、研发推进及业务拓展方面的综合表现。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","BK4007","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620780632","title":"诺华(NVS.US)拟斥资30亿美元收购Synnovation Therapeutics乳腺癌药物资产","url":"https://stock-news.laohu8.com/highlight/detail?id=2620780632","media":"智通财经","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620780632?lang=zh_cn&edition=full","pubTime":"2026-03-20 18:58","pubTimestamp":1774004312,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，诺华集团同意以最高30亿美元的价格收购Synnovation Therapeutics旗下一款实验性乳腺癌药物，以强化其肿瘤学产品管线。根据市场汇编的分析师预期，诺华目前用于治疗此类乳腺癌的药物Piqray，今年销售额预计将下滑9%，至约3.48亿美元。诺华称，该药物旨在精准靶向肿瘤细胞，同时减少对正常细胞的影响，这种策略有望\"为患者带来更好的耐受性和更持久的获益\"。截至周四，诺华股价年内累计上涨6.6%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1416688.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4007","IE00B4R5TH58.HKD","LU0070302665.USD","IE0009355771.USD","IE00BJJMRZ35.SGD","BK4578","BK4139","LENZ","BK4588","IE00BJT1NW94.SGD","BK4532","LU0211331839.USD","IE0002141913.USD","IE00B2B36J28.USD","BK4539","NVS","LU0320765489.SGD","LU0208291251.USD","BK4585","IE00BFTCPJ56.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620044915","title":"BioVie分拆的肝病药企Option Therapeutics(OPTN.US)缩减IPO规模 下调募资额20%至2000万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2620044915","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620044915?lang=zh_cn&edition=full","pubTime":"2026-03-17 15:21","pubTimestamp":1773732080,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，周一，从BioVie分拆出来的临床二期肝病生物技术公司Option Therapeutics缩减了其即将进行的IPO的规模。这家总部位于内华达州卡森城的公司现计划通过发行180万股、定价区间为10至12美元的方式募资2000万美元。以发行价区间中值计算，Option Therapeutics的募资额将比此前预期减少20%。该公司专注于开发治疗严重及危及生命的肝脏疾病的候选药物。Option Therapeutics目前尚未产生收入。Option Therapeutics成立于2025年，计划在纽约证券交易所美国板上市，股票代码为OPTN。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1414827.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LENZ","BK4539","OPTN","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618337451","title":"Aldeyra Therapeutics, Inc.盘中异动 股价大跌5.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618337451","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618337451?lang=zh_cn&edition=full","pubTime":"2026-03-12 00:08","pubTimestamp":1773245317,"startTime":"0","endTime":"0","summary":"北京时间2026年03月12日00时08分，Aldeyra Therapeutics, Inc.股票出现波动，股价快速下跌5.19%。Aldeyra Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.88%。其相关个股中，Acurx Pharmaceuticals, Inc.、Kala Bio, Inc.、天演药业涨幅较大，Acurx Pharmaceuticals, Inc.、60 Degrees Pharmaceuticals, Inc.、Quince Therapeutics, Inc.较为活跃，换手率分别为2240.92%、1066.56%、69.28%，振幅较大的相关个股有Acurx Pharmaceuticals, Inc.、天演药业、Kala Bio, Inc.，振幅分别为62.07%、56.62%、50.19%。Aldeyra Therapeutics, Inc.公司简介：Aldeyra Therapeutics Inc是一家生物技术公司，致力于开发和商业化下一代药物，以改善免疫介导和代谢疾病患者的生活。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260312000837a461b244&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260312000837a461b244&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ALDX","BK4539","BK4139","BK4007","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618765923","title":"Silence Therapeutics Plc盘中异动 股价大涨6.06%报6.65美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2618765923","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618765923?lang=zh_cn&edition=full","pubTime":"2026-03-11 22:14","pubTimestamp":1773238451,"startTime":"0","endTime":"0","summary":"北京时间2026年03月11日22时14分，Silence Therapeutics Plc股票出现波动，股价急速上涨6.06%。截至发稿，该股报6.65美元/股，成交量1.749万股，换手率0.04%，振幅5.26%。Silence Therapeutics Plc股票所在的生物技术行业中，整体跌幅为0.39%。Silence Therapeutics Plc公司简介：Silence Therapeutics PLCPLC是一家生物技术公司，专注于发现和开发含有短干扰核糖核酸或siRNA的新分子。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026031122141197add7f3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026031122141197add7f3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SLN","BK4539","BK4139","BK4007","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618968768","title":"Galectin Therapeutics Inc.盘中异动 下午盘急速跳水5.67%报3.16美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2618968768","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618968768?lang=zh_cn&edition=full","pubTime":"2026-03-11 02:08","pubTimestamp":1773166132,"startTime":"0","endTime":"0","summary":"北京时间2026年03月11日02时08分，Galectin Therapeutics Inc.股票出现异动，股价快速下挫5.67%。截至发稿，该股报3.16美元/股，成交量44.3595万股，换手率0.69%，振幅8.66%。Galectin Therapeutics Inc.股票所在的生物技术行业中，整体涨幅为1.90%。其相关个股中，Polaryx Therapeutics, Inc.、Longeveron Inc.、Cingulate Inc C/Wts 10/12/2026 涨幅较大，Longeveron Inc.、Acurx Pharmaceuticals, Inc.、Biorestorative Therapies, Inc.较为活跃，换手率分别为1100.49%、1003.30%、702.88%，振幅较大的相关个股有Polaryx Therapeutics, Inc.、Longeveron Inc.、Cingulate Inc C/Wts 10/12/2026 ，振幅分别为116.47%、109.01%、60.16%。Galectin Therapeutics Inc.公司简介：Galectin Therapeutics Inc是一家临床阶段生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026031102085297ac610b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026031102085297ac610b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["GALT","BK4139","BK4539","LENZ","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618608064","title":"Quince Therapeutics, Inc.盘中异动 早盘股价大跌5.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618608064","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618608064?lang=zh_cn&edition=full","pubTime":"2026-03-09 21:32","pubTimestamp":1773063134,"startTime":"0","endTime":"0","summary":"北京时间2026年03月09日21时32分，Quince Therapeutics, Inc.股票出现异动，股价急速下挫5.08%。Quince Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.02%。其相关个股中，Relmada Therapeutics, Inc.、Xenon制药、Dianthus Therapeutics, Inc.涨幅较大，Relmada Therapeutics, Inc.、Moolec Science Sa、Quince Therapeutics, Inc.较为活跃，换手率分别为30.31%、18.75%、13.16%，振幅较大的相关个股有Aditxt, Inc.、Reviva Pharmaceuticals Holdings, Inc.、Uniqure N.V.，振幅分别为17.03%、13.72%、12.96%。Quince Therapeutics, Inc.公司简介：Quince Therapeutics Inc 是一家临床前阶段的生物制药公司，专注于推进针对衰弱和罕见疾病的精准治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026030921321497ab242c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026030921321497ab242c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","QNCX","BK4539","LENZ","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110091863","title":"Relmada Therapeutics宣布超额认购1.6亿美元私募股权融资","url":"https://stock-news.laohu8.com/highlight/detail?id=1110091863","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1110091863?lang=zh_cn&edition=full","pubTime":"2026-03-09 19:07","pubTimestamp":1773054442,"startTime":"0","endTime":"0","summary":"佛罗里达州科勒尔盖布尔斯，2026年3月9日——临床阶段生物技术公司Relmada Therapeutics, Inc.今日宣布，已签订证券购买协议，通过非公开市场进行股权投资融资，预计将为公司带来约1.6亿美元的总收益。根据协议条款，Relmada将出售合计2947.4569万股普通股，每股作价4.75美元；同时发行421.0527万份预融资权证，每份权证定价4.749美元。Relmada作为专注于肿瘤与中枢神经系统疾病创新疗法的研发企业，其核心候选药物NDV-01和sepranolone已进入中期临床试验阶段，有望填补当前治疗领域的空白。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RLMD","BK4007","BK4139","LENZ","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618189617","title":"炎症性疾病生物技术公司Invea Therapeutics(INAI.US)撤回3500万美元IPO计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2618189617","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618189617?lang=zh_cn&edition=full","pubTime":"2026-03-09 14:29","pubTimestamp":1773037756,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，开发炎症性疾病口服小分子药物的临床阶段生物科技公司Invea Therapeutics(INAI.US)于上周五以市场状况为由，撤回了其美股首次公开募股计划。该公司此前提交的招股书显示，拟以每股10至12美元的价格发行320万股，募资3500万美元。这家总部位于康涅狄格州吉尔福德的公司成立于2021年，原计划在纳斯达克上市，股票代码为INAI。ThinkEquity原定为该交易的独家账簿管理人。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1411525.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4139","LENZ","BK4007","INAI","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618611853","title":"Lineage Cell Therapeutics, Inc.2025财年实现净利润-63.53百万美元，同比减少241.38%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618611853","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618611853?lang=zh_cn&edition=full","pubTime":"2026-03-09 00:01","pubTimestamp":1772985680,"startTime":"0","endTime":"0","summary":"3月9日，Lineage Cell Therapeutics, Inc.公布财报，公告显示公司2025财年净利润为-63.53百万美元，同比减少241.38%；其中营业收入为14.56百万美元，同比增加53.26%，每股基本收益为-0.28美元。从资产负债表来看，Lineage Cell Therapeutics, Inc.总负债69.24百万美元，其中短期债务853000.00美元，资产负债比为0.02，流动比率为5.21。机构评级：截至2026年3月9日，当前有5家机构对Lineage Cell Therapeutics, Inc.目标价做出预测，其中目标均价为4.60美元，其中最低目标价为3.00美元，最高目标价为9.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260309000152a4587951&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260309000152a4587951&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","LINE"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://ir.lenz-tx.com","stockEarnings":[{"period":"1week","weight":-0.0786},{"period":"1month","weight":0.0342},{"period":"3month","weight":-0.5411},{"period":"6month","weight":-0.7066},{"period":"1year","weight":-0.6721},{"period":"ytd","weight":-0.4137}],"compareEarnings":[{"period":"1week","weight":0.0054},{"period":"1month","weight":0.087},{"period":"3month","weight":0.0359},{"period":"6month","weight":0.0542},{"period":"1year","weight":0.3059},{"period":"ytd","weight":0.047}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"LENZ Therapeutics, Inc.最初于2017年6月1日在加拿大安大略省注册成立，随后于2019年10月在特拉华州重新注册成立。该公司是一家商业制药公司，专注于开发和商业化改善视力的疗法，其主导产品VIZZ被批准用于治疗老花眼。","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":-0.137955},{"month":2,"riseRate":0.4,"avgChangeRate":0.032476},{"month":3,"riseRate":0.2,"avgChangeRate":-0.143415},{"month":4,"riseRate":0.6,"avgChangeRate":-0.012956},{"month":5,"riseRate":0.25,"avgChangeRate":-0.134416},{"month":6,"riseRate":0.75,"avgChangeRate":0.05507},{"month":7,"riseRate":0.6,"avgChangeRate":0.05308},{"month":8,"riseRate":0.4,"avgChangeRate":0.016536},{"month":9,"riseRate":0.6,"avgChangeRate":0.026875},{"month":10,"riseRate":0.6,"avgChangeRate":-0.067546},{"month":11,"riseRate":0.6,"avgChangeRate":-0.005451},{"month":12,"riseRate":0.4,"avgChangeRate":-0.038411}],"exchange":"NASDAQ","name":"Therapeutics","nameEN":"Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Therapeutics(LENZ)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Therapeutics(LENZ)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Therapeutics,LENZ,Therapeutics股票,Therapeutics股票老虎,Therapeutics股票老虎国际,Therapeutics行情,Therapeutics股票行情,Therapeutics股价,Therapeutics股市,Therapeutics股票价格,Therapeutics股票交易,Therapeutics股票购买,Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Therapeutics(LENZ)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Therapeutics(LENZ)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}